Gilead’s Biktarvy shows durable viral suppression in HIV-1 trial
Gilead Sciences has reported that new long-term data from open-label extensions (OLE) of two Phase...
Ridgeback and Merck report preliminary data from Covid-19 trial
Merck and Ridgeback Biotherapeutics have reported preliminary results from a Phase IIa trial of investigational...
Lilly’s tirzepatide leads to body weight reductions in type 2 diabetes trial
Eli Lilly and Company has reported that results from the SURPASS-2 clinical trial of tirzepatide...
COSELA™ (trilaciclib) for the Treatment of Chemotherapy-Induced Myelosuppression, US
COSELA™ (trilaciclib) is the first approved myeloprotection therapy indicated to reduce the occurrence of chemotherapy-induced...
Dicerna and Roche start Phase II trial of GalXC RNAi candidate in hepatitis B
Dicerna Pharmaceuticals and Roche have commenced the Phase II combination trial of investigational GalXC RNAi...
Marker Therapeutics treats first subject in acute myeloid leukaemia trial
Marker Therapeutics has treated the first patient in its Phase II trial of its lead...
Lilly’s baricitinib meets primary endpoint in alopecia areata trial
Eli Lilly and Company and Incyte have reported positive top-line results from Phase III BRAVE-AA2...
Vir and GSK to halt enrolment in Covid-19 antibody trial
Vir Biotechnology and GlaxoSmithKline (GSK) have reported that the independent Data and Safety Monitoring Board...
Amgen reports positive data from BLINCYTO study in leukaemia patients
Amgen has reported positive data from the Phase III study of BLINCYTO (blinatumomab) in paediatric...
Merck withdraws Keytruda from SCLC indication amid FDA crackdown
On 1 March, Merck announced the voluntary withdrawal of its Keytruda (pembrolizumab) immunotherapy for the...